OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis
doi 10.1136/annrheumdis-2017-eular.2220
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism